DISCOVER _V1

• Research type

  Research Study

• Full title

  DISCOVER: DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

• IRAS ID

  170044

• Contact name

  Mustafa Dungarwalla

• Contact email

  mustafa.dungarwalla@cegedim.com

• Sponsor organisation

  AstraZeneca

• Clinicaltrials.gov Identifier

  NCT02322762, Registration on clinicaltrail.gov

• Duration of Study in the UK

  4 years, 6 months, 31 days

• Research summary

  In many geographical regions, there is a lack in data on diabetes treatments and control, and when information is available, it does not contain enough detail to describe patient clinical progression over time. Little has been published since the launch of newer classes of type 2 diabetes medicines (such as DPP-IV inhibitors, GLP-1 agonists and most recently the SGLT2 inhibitors), as compared to older medications, such as oral hypoglyacemic agents sulphonylureas and metformin.

  Hence, this study aims to provide data on real world progression and clinical outcomes for patients that are starting their second medicine for type 2 diabetes.
  Patients will be recruited into the study from over 30 countries, including the UK. In the UK, a total of 500 patients will be enrolled, who will contribute with relevant information to a global cohort of approximately 9,650 patients.

  The study will last for three years, with patients recruited upon first prescribing of the second anti-diabetic medicine and followed up at four time points after that (at 6, 12, 24 and 36 months). Eligible patients will be introduced to the study and will be given information before choosing whether or not to participate. If patients consent to participate, their GP will collect data regarding their medical history and other relevant clinical data. Patients will also be asked at their visits to fill in questionnaires to report specific aspects related to their quality of life. In addition, information available in the patient electronic medical records will be captured.

  Patients will not undergo any clinical examinations specific to the study and will not be asked to take any medications as a result of being in the study. The study will be purely observational and patients should experience the same treatment and physician consultation, regardless of whether or not they agree to participate.

• REC name

  West Midlands - Solihull Research Ethics Committee

• REC reference

  15/WM/0058

• Date of REC Opinion

  12 Feb 2015

• REC opinion

  Favourable Opinion